The Significance of Matrix Metalloproteinase 9 (MMP-9) and Metalloproteinase 2 (MMP-2) in Urinary Bladder Cancer.
MMP-2
MMP-9
biomarker
gelatinase
urinary bladder carcinoma
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
20 Mar 2023
20 Mar 2023
Historique:
received:
07
03
2023
revised:
16
03
2023
accepted:
17
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Urinary bladder cancer is a serious oncological problem that is the cause of many deaths worldwide. The processes of metastasis and origination of local tumor invasion depend on the extracellular matrix (ECM) degradation. The cancer microenvironment, particularly the ECM, may be considered a key factor in cancer progression. Matrix metalloproteinases (MMPs) are classified as the main factors responsible for the degradation of ECM components. Therefore, the aim of the study was to evaluate the expression and activity of matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9) in urinary bladder cancer according to different stages. Urinary bladder tissue samples were analyzed. Cancer patients were divided into two groups: low-grade tumors (LG; Group I) and high-grade tumors (HG; Group II). Control tissue was obtained from the opposite site to the tumor. MMPs content and activity (actual and specific) were evaluated using ELISA and Western blot methods, respectively. Both MMPs are present in high and low molecular complexes in healthy or bladder cancer tissues. The content of MMP-9 is enhanced in comparison with MMP-2, particularly in HG cancer tissue. The actual activity of MMP-2 was highest in LG cancer tissue whereas the actual activity of MMP-9 was highest in HG cancer. Specific activity of both MMPs was highest in LG cancer, but the activity of MMP-9 was higher in comparison with MMP-2. In conclusion, the content and specific activity of MMP-9 were increased in comparison with MMP-2. The revealed differences in content and activity of both MMPs demonstrate their different participation in ECM remodeling at different stages of cancer development. Moreover, it seems that MMP-9 has higher clinical utility than MMP-2 as a potential therapeutic option and a diagnostic biomarker of urinary bladder cancer.
Identifiants
pubmed: 36979935
pii: biomedicines11030956
doi: 10.3390/biomedicines11030956
pmc: PMC10046406
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Pol J Pathol. 2014 Mar;65(1):55-9
pubmed: 25119010
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
Eur Urol. 2022 Jan;81(1):75-94
pubmed: 34511303
Front Oncol. 2019 Dec 06;9:1370
pubmed: 31921634
Nat Rev Urol. 2009 Nov;6(11):596-611
pubmed: 19890339
Actas Urol Esp. 2013 Sep;37(8):480-8
pubmed: 23916137
J Urol. 1999 Apr;161(4):1359-63
pubmed: 10081908
Cancer Res. 1993 Nov 15;53(22):5365-9
pubmed: 8221672
Oncotarget. 2016 Dec 13;7(50):82609-82619
pubmed: 27655672
Anticancer Res. 2000 May-Jun;20(3B):2009-13
pubmed: 10928143
Urology. 2003 Nov;62(5):952-7
pubmed: 14624933
Nature. 1970 Aug 15;227(5259):680-5
pubmed: 5432063
Anticancer Res. 2008 May-Jun;28(3B):1757-61
pubmed: 18630455
J Biochem Mol Toxicol. 2019 Apr;33(4):e22275
pubmed: 30548095
Clin Chim Acta. 2000 Sep;299(1-2):11-23
pubmed: 10900289
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
Urology. 2001 Apr;57(4):675-9
pubmed: 11306379
Tumour Biol. 2008;29(5):279-86
pubmed: 18802398
J Cell Biol. 1986 Sep;103(3):1021-31
pubmed: 3017994
Prog Mol Biol Transl Sci. 2017;147:1-73
pubmed: 28413025
Med Sci (Basel). 2020 Mar 13;8(1):
pubmed: 32183076
Bioorg Med Chem. 2009 Jan 15;17(2):653-9
pubmed: 19109023
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cancer Res. 2006 Dec 15;66(24):11644-8
pubmed: 17178858
Int J Biol Markers. 2010 Apr-Jun;25(2):69-74
pubmed: 20586027
Int J Exp Pathol. 2019 Apr;100(2):94-101
pubmed: 31058412
Cancer Control. 2018 Jan-Dec;25(1):1073274818789357
pubmed: 30037277
Eur Urol. 2007 Nov;52(5):1388-96
pubmed: 17466450
J Clin Med. 2021 Aug 19;10(16):
pubmed: 34441979
Biochim Biophys Acta. 2012 Jan;1825(1):29-36
pubmed: 22020293
Urol Int. 2012;89(3):342-7
pubmed: 23006800
Cancer. 1996 Dec 1;78(11):2379-87
pubmed: 8941010
Acta Biochim Pol. 2021 Jul 27;68(4):547-555
pubmed: 34314132
J Cancer Res Ther. 2018;14(Supplement):S54-S59
pubmed: 29578150
BJU Int. 2000 Sep;86(4):553-7
pubmed: 10971291
Cells. 2020 Apr 26;9(5):
pubmed: 32357580
Biomark Insights. 2007 Nov 05;2:418-27
pubmed: 19662222
Urology. 2003 Apr;61(4):719-23
pubmed: 12670552
Clin Cancer Res. 2000 Jun;6(6):2333-40
pubmed: 10873084